Does Stanford’s 5-day TMS protocol work for treatment-resistant depression?
Yes, on the primary outcome of this trial. Stanford Neuromodulation Therapy produced a mean 52.5% reduction in depression scores 4 weeks after treatment, compared with 11.1% after sham stimulation. The double-blind randomized controlled trial randomized patients with treatment-resistant depression to active or sham SNT, and at the planned interim analysis 32 participants had been enrolled, with 29 going on to receive treatment (14 active, 15 sham).
SNT works by using resting-state functional MRI to personalize targeting: the stimulation site is the region of the left dorsolateral prefrontal cortex most functionally anticorrelated with the subgenual anterior cingulate cortex. It delivers accelerated, high-dose intermittent theta-burst stimulation over 5 days rather than the 6 weeks required by the standard FDA-approved iTBS course.
What the data show:
- Depression reduction: mean 52.5% reduction in MADRS scores 4 weeks after treatment with active SNT vs. 11.1% with sham
- Study scope: 32 participants enrolled at the planned interim analysis, 29 treated (14 active, 15 sham), all with treatment-resistant depression and current moderate to severe depressive episodes
- Targeting: individualized left dorsolateral prefrontal cortex target chosen by functional connectivity with the subgenual anterior cingulate cortex
- Prior signal: the same protocol was associated with a remission rate of about 90% after 5 days of open-label, uncontrolled treatment
This double-blind randomized controlled trial, published in the American Journal of Psychiatry, was designed to test whether the open-label results held up against sham stimulation. On the primary outcome, MADRS score 4 weeks after treatment, active SNT outperformed sham.
Dr. Kumar’s Take
The interesting part of this protocol is not the theta-burst waveform, it is the engineering around it. Compressing a 6-week course into 5 days and picking each patient’s target from their own functional connectivity map is precision medicine applied to brain stimulation, and I want to see more of psychiatry move in that direction. I also want to keep the claim sized to the data. This is an interim analysis of a small sham-controlled trial, and the headline number people repeat, roughly 90% remission, comes from the earlier open-label experience, not from this randomized comparison. What the randomized comparison shows is a substantially larger drop in depression scores at 4 weeks with active stimulation than with sham. For a patient who has already failed multiple medications, that is a meaningful result and a reasonable reason to ask about accelerated iTBS. It is not yet a reason to promise remission in a week. The authors themselves say further trials are needed to establish durability and to compare SNT with other treatments, and I would tell a patient exactly that before they rearrange their life around a 5-day protocol.
Study Snapshot
This double-blind randomized controlled trial investigated Stanford Neuromodulation Therapy, a neuroscience-informed accelerated intermittent theta-burst stimulation protocol for treatment-resistant depression. The protocol was previously referred to as Stanford accelerated intelligent neuromodulation therapy, or SAINT. Participants with treatment-resistant depression who were currently experiencing moderate to severe depressive episodes were randomly assigned to receive active or sham SNT. Resting-state functional MRI was used to individually target the region of the left dorsolateral prefrontal cortex most functionally anticorrelated with the subgenual anterior cingulate cortex.
Results in Real Numbers
At the planned interim analysis, 32 participants with treatment-resistant depression had been enrolled. 29 participants continued to meet inclusion criteria and received treatment: 14 in the active SNT group and 15 in the sham group.
The primary outcome was the Montgomery-Åsberg Depression Rating Scale score 4 weeks after treatment. The mean percent reduction from baseline in MADRS score at that point was 52.5% in the active treatment group and 11.1% in the sham treatment group. The authors concluded that SNT, a high-dose iTBS protocol with functional-connectivity-guided targeting, was more effective than sham stimulation for treatment-resistant depression.
For context on why the protocol was developed this way: iTBS is already approved by the U.S. Food and Drug Administration for treatment-resistant depression, but the standard course is limited by suboptimal efficacy and a 6-week duration. Depression is the leading cause of disability worldwide, and half of patients with depression have treatment-resistant depression.
Who Benefits Most
Patients with treatment-resistant depression who are in a current moderate to severe depressive episode are the population this trial actually studied, so they are the group the findings speak to most directly. Anyone who cannot commit to a 6-week course of standard iTBS, or who needs treatment delivered over a shorter window, has an obvious reason to ask about an accelerated protocol.
Because the target is selected from each patient’s own resting-state functional MRI, SNT also suits patients who have access to a center capable of doing that imaging and translating it into a stimulation target.
Safety, Limits, and Caveats
The main limits are the ones the authors name. These results come from a planned interim analysis of a small trial: 29 treated participants split across active and sham. Further trials are needed to determine how durable the response is, since the primary outcome was measured 4 weeks after treatment, and to compare SNT with other treatments.
The protocol also requires resting-state functional MRI and the expertise to derive an individualized left dorsolateral prefrontal cortex target from it, so it is not something every TMS center can deliver. The roughly 90% remission figure that circulates with this protocol came from open-label treatment without a sham comparison, and it should not be quoted as the result of this randomized trial.
Practical Takeaways
- Ask about accelerated, functional-connectivity-guided iTBS if you have treatment-resistant depression and have failed multiple medication trials
- Understand the timeline difference: SNT delivers treatment over 5 days, while the standard FDA-approved iTBS course runs 6 weeks
- Expect the target to be chosen from your own functional MRI, which means the treating center needs imaging capability, not just a TMS coil
- Judge the protocol on the sham-controlled result, a 52.5% mean MADRS reduction versus 11.1%, rather than on the open-label remission figure
- Treat durability as an open question and plan follow-up accordingly, since the primary outcome was measured 4 weeks after treatment
What This Means for Depression Treatment
This trial supports the core idea behind SNT: that individualizing the stimulation target by functional connectivity and delivering a high dose over a compressed schedule can beat sham stimulation in treatment-resistant depression. That is a meaningful step for a condition where half of patients do not respond adequately to medication.
It also sets the agenda for what comes next. The authors call for trials that establish durability and that compare SNT directly with other treatments. Until those exist, accelerated fMRI-guided iTBS is a promising option with one blinded, sham-controlled trial behind it, not a settled standard of care.
Related Studies and Research
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
FAQs
Where does the 90% remission figure come from?
From open-label treatment with this protocol, which was associated with a remission rate of about 90% after 5 days. It is not the result of this sham-controlled randomized trial, whose primary outcome was a 52.5% mean reduction in MADRS score at 4 weeks versus 11.1% with sham.
How does SNT differ from standard TMS?
Standard FDA-approved iTBS for treatment-resistant depression runs 6 weeks. SNT is a high-dose accelerated version delivered over 5 days, with the left dorsolateral prefrontal cortex target chosen from each patient’s resting-state functional MRI based on anticorrelation with the subgenual anterior cingulate cortex.
How long does the benefit last?
The primary outcome was measured 4 weeks after treatment. The authors state that further trials are needed to determine SNT’s durability and to compare it with other treatments.
Bottom Line
In a double-blind, sham-controlled trial of 29 treated patients with treatment-resistant depression, 5 days of functional-connectivity-guided accelerated iTBS produced a 52.5% mean reduction in MADRS scores at 4 weeks versus 11.1% with sham. That makes SNT more effective than sham in this interim analysis, with durability and head-to-head comparisons still to be established.
